BEYONDSPRING INC (BYSI) Stock Price, Quote, News and Overview
NASDAQ:BYSI - Nasdaq - KYG108301006 - Common Stock - Currency: USD
BYSI Quote, Performance and Key Statistics
1.57
-0.03 (-1.88%)
The current stock price of BYSI is 1.57 USD. In the past month the price increased by 9.03%. In the past year, price decreased by -30.22%.
BYSI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.73 | 340.25B | ||
| AMGN | AMGEN INC | 14.28 | 152.20B | ||
| GILD | GILEAD SCIENCES INC | 13.74 | 132.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1712.03 | 127.64B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.38 | 66.78B | ||
| ARGX | ARGENX SE - ADR | 326.83 | 37.92B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.15B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.00B | ||
| NTRA | NATERA INC | N/A | 20.68B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.78B | ||
| BIIB | BIOGEN INC | 7.23 | 17.44B |
Related stock screener links
About BYSI
Company Profile
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 40 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Company Info
BEYONDSPRING INC
100 Campus Drive, West Side, 4Th Floor, Suite 410
Florham Park NEW JERSEY 10005 US
CEO: Lan Huang
Employees: 36
Company Website: https://www.beyondspringpharma.com/en/
Investor Relations: https://beyondspringpharma.com/stock-overview/
Phone: 16465284184
BEYONDSPRING INC / BYSI FAQ
What is the stock price of BEYONDSPRING INC today?
The current stock price of BYSI is 1.57 USD. The price decreased by -1.88% in the last trading session.
What is the ticker symbol for BEYONDSPRING INC stock?
The exchange symbol of BEYONDSPRING INC is BYSI and it is listed on the Nasdaq exchange.
On which exchange is BYSI stock listed?
BYSI stock is listed on the Nasdaq exchange.
What is BEYONDSPRING INC worth?
BEYONDSPRING INC (BYSI) has a market capitalization of 63.30M USD. This makes BYSI a Micro Cap stock.
How many employees does BEYONDSPRING INC have?
BEYONDSPRING INC (BYSI) currently has 36 employees.
What are the support and resistance levels for BEYONDSPRING INC (BYSI) stock?
BEYONDSPRING INC (BYSI) has a support level at 1.56 and a resistance level at 1.68. Check the full technical report for a detailed analysis of BYSI support and resistance levels.
Should I buy BEYONDSPRING INC (BYSI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BYSI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BYSI, evaluating the profitability, health, valuation and growth aspects
- BEYONDSPRING INC (BYSI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BEYONDSPRING INC (BYSI) Sales and EPS estimates to see what analysts future expectations are.
- BEYONDSPRING INC (BYSI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BEYONDSPRING INC (BYSI) Insider and Institutional Ownership to learn about the owners and their transactions.
- BEYONDSPRING INC (BYSI) Stock Chart to make your own analysis
- BEYONDSPRING INC (BYSI) Latest news and press-releases to stay up to date.
Does BEYONDSPRING INC (BYSI) stock pay dividends?
BYSI does not pay a dividend.
What is the Price/Earnings (PE) ratio of BEYONDSPRING INC (BYSI)?
BEYONDSPRING INC (BYSI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.27).
What is the Short Interest ratio of BEYONDSPRING INC (BYSI) stock?
The outstanding short interest for BEYONDSPRING INC (BYSI) is 5.36% of its float. Check the ownership tab for more information on the BYSI short interest.
BYSI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BYSI. When comparing the yearly performance of all stocks, BYSI is a bad performer in the overall market: 78.34% of all stocks are doing better.
BYSI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BYSI. BYSI has a bad profitability rating. Also its financial health evaluation is rather negative.
BYSI Financial Highlights
Over the last trailing twelve months BYSI reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 49.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.41% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BYSI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to BYSI. The Buy consensus is the average rating of analysts ratings from 7 analysts.